PHARMA · MARKET ACCESS · GERMANY

Getting authorized is the ticket. Getting reimbursed is the work.
Create a targeted live campaign. Scale your infrastructure with our simple service.
Book a session
How it works
Germany is among the largest pharmaceutical markets in Europe and, for most companies, the first serious step into the EU. But a marketing authorization is only the entry ticket. Commercial outcome is decided downstream — in the reimbursement decision, the negotiated price, the distribution channel and the local relationships that German payers, wholesalers and hospitals expect. Getting authorized and getting paid are two different projects, and most market-entry failures happen in the gap between them.
Medical devices, diagnostics and digital health applications run on a different track (MDR, CE marking, DiGA fast-track). We handle those separately — see 〔link: Medtech & Diagnostics page〕 — rather than pretend one playbook covers both.

The decision that actually shapes your German launch: reimbursement

GA new patented medicine enters the German statutory market under AMNOG (Arzneimittelmarktneuordnungsgesetz). In practice this means:

  • You set your launch price freely for the first months.

  • You submit a benefit dossier to the G-BA (Gemeinsamer Bundesausschuss / Federal Joint Committee).

  • The IQWiG assesses your product's added benefit (Zusatznutzen) against a defined comparator (zweckmäßige Vergleichstherapie).

  • The GKV-Spitzenverband (umbrella of statutory health insurers) then negotiates the reimbursement amount (Erstattungsbetrag).

  • No demonstrated added benefit usually means assignment to a reference-price group (Festbetrag) — i.e. a hard ceiling on revenue.

  • This single process — not your home-market price, not your sales effort — sets the ceiling on what Germany will pay. It should shape your positioning, comparator choice and evidence narrative from day one. Companies that treat reimbursement as a post-launch formality discover the ceiling after they have already built the cost base.

Regulatory authorization: the entry ticket, not the strategy

Germany is the largest pharmaceutical market in Europe, with annual pharmaceutical sales exceeding €60 billion and strong demand across prescription drugs, biotech products, diagnostics and medical technologies.

Key drivers include:

  • ageing population and long-term healthcare demand
  • strong reimbursement system
  • highly developed hospital infrastructure
  • large private and public healthcare sectors
  • central role in EU pharmaceutical distribution

Germany is also a strategic base for broader EU market expansion due to its logistics and regulatory position.
BCA Market Intelligence
Regulatory and Market Access Requirements
Germany’s life sciences market is highly regulated and aligned with EU law.

Key regulatory frameworks include:

  • EU GMP requirements
  • EU Medical Device Regulation (MDR) 2017/745
  • CE marking for devices
  • pharmacovigilance and product safety obligations
  • GDP (Good Distribution Practice) for pharma logistics

Additional German requirements may include:

  • local registration procedures
  • reimbursement pathways
  • hospital procurement standards
  • healthcare marketing compliance

Market entry without regulatory preparation often results in delays and commercial barriers.

Practical Approach

  • Distributor / Importer Model

    Suitable for companies seeking faster access with limited local setup.

  • Direct Subsidiary / GmbH

    Preferred for long-term presence, clinical support and direct commercial control.

  • Local Representative / Market Support

    Used for early-stage market testing, partner management and local coordination.

  • Hybrid Entry Model

    Combining distributors with direct key account management is common in medtech and diagnostics.

Germany’s pharma and life sciences market offers strong commercial potential, but market entry is rarely immediate.

Companies that succeed usually combine regulatory preparation, local market knowledge and structured commercial execution rather than relying on generic EU entry assumptions.
Important: Partnerships in Germany are usually developed over time. Initial cooperation may begin with limited scope before expanding into broader distribution agreements.

Trust, reliability and consistency are critical factors. Many distributors prefer long-term relationships over short-term commercial opportunities.
Entering Germany’s Pharma and Life Sciences Market?
Tell us about your product and target market, and we will help you identify and approach suitable distributors in Germany.
Privacy Policy confirmation
International clients from Europe, Asia and the Middle East.